Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10518765 | 1.00 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL3046354 | 1.00 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL6152103 | 1.00 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL10518635 | 0.93 | CYP3A4 (0.39) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL13701349 | 0.90 | CYP3A4 (0.39) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL13701326 | 0.90 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL13701359 | 0.90 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL13701348 | 0.90 | CYP3A4 (0.39) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| SCHEMBL13701350 | 0.90 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 | |
| Hydrochloric Acid SCHEMBL6151963 | 0.84 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130237705-A1 | METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES | PETERSON JOHN R (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130225817-A1 | METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES | PETERSON JOHN R (US) | 2013-08-29 | — | — | US | disclosed |
| US-8431699-B2 | Method for manufacture of 2-oxoimidazolidines | Vertichem Corporation (CA) | 2013-04-30 | — | — | US | disclosed |
| US-20100222588-A1 | Method for Manufacture of 2-Oxoimidazolidines | THESIS CHEMISTRY, LLC (US) | 2010-09-02 | — | — | US | disclosed |
| EP-1068200-B1 | 2,4,4-TRISUBSTITUTED-1,3-DIOXOLANE ANTIFUNGALS | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-6387906-B1 | DERMATOPHYTES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-14 | — | — | US | disclosed |
| EP-0741737-B1 | WATERSOLUBLE AZOLE ANTIFUNGALS | JANSSEN PHARMACEUTICA NV (BE) | 1999-11-10 | — | — | EP | disclosed |
| EP-0278105-B1 | 2,4,4-TRI- AND 2,2,4,4-TETRA-SUBSTITUTED-1,3-DIOXOLANE | SCHERING CORP (US) | 1992-05-06 | — | — | EP | disclosed |
| EP-0329711-A1 | 2,4,4-TRI- AND 2,2,4,4-TETRA SUBSTITUTED-1,3-DIOXOLANE COMPOUNDS | SCHERING CORPORATION (US) | 1989-08-30 | — | — | EP | disclosed |
| US-4788190-A | 2,4,4-tri- and 2,2,4,4-tetra substituted-1,3-dioxolane antifungal, antiallergy compounds | SCHERING CORPORATION (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0278105-A1 | 2,4,4-Tri- and 2,2,4,4-tetra-substituted-1,3-dioxolane | SCHERING CORPORATION (US) | 1988-08-17 | — | — | EP | disclosed |
| WO-1988005048-A1 | 2,4,4-TRI- AND 2,2,4,4-TETRA SUBSTITUTED-1,3-DIOXOLANE COMPOUNDS | SCHERING CORPORATION (US) | 1988-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237705-A1 | METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES | ODC1, NISCH, IMPDH2 | CYP3A4 6/4885CYP2C9 36/4885CYP2C19 76/4885 |
| US-20100222588-A1 | Method for Manufacture of 2-Oxoimidazolidines | ODC1, CBR3, CBR1 | CYP3A4 35/4885CYP2C9 81/4885CYP2C19 87/4885 |
| US-20130225817-A1 | METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES | ODC1, NISCH, IMPDH2 | CYP3A4 6/4885CYP2C9 36/4885CYP2C19 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.